Twist Bioscience’s stock has experienced a downturn despite the company announcing a strategic spin-out of its DNA data storage division into Atlas Data Storage, securing $155 million in investments. The spin-out is aimed at allowing Twist to focus on its core operations while maintaining a stake in Atlas for potential future gains. Additionally, Twist reported a record revenue of $92.8 million for Q2 of fiscal 2025, marking a 23% increase from the previous year, along with an improved gross margin of 49.6%. However, analysts have lowered price targets due to ongoing concerns about profitability, cash flow, and valuation issues, particularly a negative P/E ratio. The company remains hopeful about reaching adjusted EBITDA breakeven by the end of fiscal 2026 through continued growth and innovation.
https://www.tipranks.com/news/catalyst/why-twist-bioscience-shares-are-dropping-now
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.